Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
The tumor microenvironment (TME) constitutes the tumor, extracellular matrix (ECM) and several non-transformed cells, such as immune infiltrates, fibroblasts and vascular vessels recruited from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback